Compugen Ltd (Nasdaq: CGEN) (TASE: CGEN) an Israeli clinical-stage cancer immunotherapy company involved in computational target discovery, announced on Wednesday that the United States Patent and Trademark Office (USPTO) has granted a new patent covering method of use for COM902, the company's potential best-in-class reduced Fc, clinical stage antibody aimed at TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer.

US Patent No. 12152084 is titled 'Triple combination antibody therapies'. It augments patents previously issued to Compugen by expanding and protecting the use of COM902 and backup antibodies for treating cancer patients, to include the triplet combination of COM902 with any anti-PD-1 antibody and any anti-PVRIG antibody.

The patent is expected to expire no earlier than August 2037 in the United States.